NASDAQ:EWTX Edgewise Therapeutics (EWTX) Stock Price, News & Analysis $17.52 +0.05 (+0.29%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$17.02▼$17.5950-Day Range$15.88▼$22.8752-Week Range$5.12▼$23.50Volume733,582 shsAverage Volume863,535 shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$33.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Edgewise Therapeutics alerts: Email Address Edgewise Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside90.6% Upside$33.40 Price TargetShort InterestHealthy10.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.48) to ($1.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.65 out of 5 starsMedical Sector616th out of 910 stocksPharmaceutical Preparations Industry284th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingEdgewise Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEdgewise Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Edgewise Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.97% of the float of Edgewise Therapeutics has been sold short.Short Interest Ratio / Days to CoverEdgewise Therapeutics has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Edgewise Therapeutics has recently decreased by 20.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEdgewise Therapeutics does not currently pay a dividend.Dividend GrowthEdgewise Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EWTX. Previous Next 1.7 News and Social Media Coverage News SentimentEdgewise Therapeutics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Edgewise Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for EWTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Edgewise Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edgewise Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders24.11% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Edgewise Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.48) to ($1.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edgewise Therapeutics is -11.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Edgewise Therapeutics is -11.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEdgewise Therapeutics has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edgewise Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Edgewise Therapeutics Stock (NASDAQ:EWTX)Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Read More EWTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EWTX Stock News HeadlinesSeptember 3, 2024 | msn.comDyne stock tumbles 31% amid drug updates, management changesAugust 30, 2024 | americanbankingnews.comReviewing Edgewise Therapeutics (NASDAQ:EWTX) & Regeneron Pharmaceuticals (NASDAQ:REGN)September 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 13, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Insulet (PODD), Recursion Pharmaceuticals (RXRX) and Edgewise Therapeutics (EWTX)August 8, 2024 | finance.yahoo.comEdgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 6, 2024 | seekingalpha.comEdgewise Therapeutics: Strong Open Label Data Makes For A Bullish SignalJuly 30, 2024 | investorplace.com7 Small-Cap Stocks to Buy for Large-Scale GainsJuly 30, 2024 | markets.businessinsider.comAnalyst Reaffirms Buy Rating on Edgewise Therapeutics Amid Market SpeculationSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.July 27, 2024 | msn.com3 Best Stocks to Buy Now, 7/26/2024, According to Top AnalystsJuly 25, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Edgewise Therapeutics (EWTX)May 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Edgewise Therapeutics (EWTX) and Forte Biosciences (FBRX)May 10, 2024 | finance.yahoo.comEdgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial ResultsMay 10, 2024 | businesswire.comEdgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024May 9, 2024 | investorplace.comEWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q1 2024May 6, 2024 | businesswire.comEdgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)April 23, 2024 | businesswire.comEdgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular DystrophiesApril 22, 2024 | seekingalpha.comJANX Janux Therapeutics, Inc.See More Headlines Receive EWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EWTX CUSIPN/A CIK1710072 Webwww.edgewisetx.com Phone720-262-7002FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$33.40 High Stock Price Target$48.00 Low Stock Price Target$25.00 Potential Upside/Downside+90.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.01% Return on Assets-26.69% Debt Debt-to-Equity RatioN/A Current Ratio30.24 Quick Ratio30.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.44 per share Price / Book3.22Miscellaneous Outstanding Shares93,399,000Free Float70,881,000Market Cap$1.64 billion OptionableOptionable Beta0.15 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Chairman Comp: $76kDr. Kevin Koch Ph.D. (Age 64)President, CEO & Director Comp: $905.52kDr. Badreddin Edris Ph.D. (Age 37)Co-Founder & Independent Director Comp: $43kDr. Behrad Derakhshan Ph.D. (Age 44)Chief Business Officer Comp: $630.67kDr. Joanne M. Donovan M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $696.4kDr. Alan J. Russell Ph.D. (Age 54)Co-Founder, Chief Scientific Officer & Director Comp: $657.52kMr. R. Michael Carruthers (Age 66)Chief Financial Officer Comp: $386.01kMr. John R. Moore (Age 60)General Counsel Dr. Marc Semigran M.D. (Age 67)Chief Development Officer More ExecutivesKey CompetitorsZogenixNASDAQ:ZGNXKura OncologyNASDAQ:KURAAnaptysBioNASDAQ:ANABIntersect ENTNASDAQ:XENTArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsNovo Holdings A SBought 6,344,430 shares on 8/20/2024Ownership: 6.793%Frazier Life Sciences Management L.P.Bought 427,500 shares on 8/16/2024Ownership: 3.995%Perceptive Advisors LLCSold 463,229 shares on 8/16/2024Ownership: 1.988%Driehaus Capital Management LLCSold 7,427 shares on 8/16/2024Ownership: 1.349%Quarry LPBought 14,000 shares on 8/16/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions EWTX Stock Analysis - Frequently Asked Questions How have EWTX shares performed this year? Edgewise Therapeutics' stock was trading at $10.94 on January 1st, 2024. Since then, EWTX shares have increased by 60.1% and is now trading at $17.52. View the best growth stocks for 2024 here. How were Edgewise Therapeutics' earnings last quarter? Edgewise Therapeutics, Inc. (NASDAQ:EWTX) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.02. When did Edgewise Therapeutics IPO? Edgewise Therapeutics (EWTX) raised $150 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO. Who are Edgewise Therapeutics' major shareholders? Edgewise Therapeutics' top institutional shareholders include Novo Holdings A S (6.79%), Frazier Life Sciences Management L.P. (3.99%), Perceptive Advisors LLC (1.99%) and Driehaus Capital Management LLC (1.35%). Insiders that own company stock include Peter A Thompson, Orbimed Advisors Llc, Holdings A/S Novo, R Michael Carruthers, Joanne M Donovan, Kevin Koch, Behrad Derakhshan, Alan J Russell and John R Moore. View institutional ownership trends. How do I buy shares of Edgewise Therapeutics? Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EWTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
